AMGEN PRESENTS NEW RESEARCH ON OTEZLA® (APREMILAST) IN PSORIATIC ARTHRITIS AT EULAR 2023

/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new research examining the use of Otezla® (apremilast) in psoriatic arthritis, including the Phase 4 MOSAIC...

Related Keywords

Milan ,Lombardia ,Italy ,Denmark ,Copenhagen ,Køavn ,Puerto Rico ,United States ,America ,Ponda Motsepe Ditshego ,Michael Strapazon ,Jessica Akopyan ,University Of Copenhagen ,Arthritis Research ,Linkedin ,Teneobio Inc ,Kyowa Kirin Co Ltd ,Amgen ,Therapeutics Inc ,Copenhagen Center ,Beigene Ltd ,National Psoriasis Foundation ,European Congress ,Twitter ,Most Sustainable Companies ,Instagram ,Drug Administration ,Exchange Commission ,Youtube ,Chemocentryx Inc ,Assess Inflammation ,Peripheral Joints ,Psoriatic Arthritis Patients ,Analysis Examines Effects ,Cardiometabolic Parameters ,Global Medical ,Professor Mikkel ,Spine Diseases ,Clinical Disease Activity Index ,Psoriatic Arthritis ,Poster Tour Session ,Apremilast Reduces Inflammation ,Primary Results ,About Psoriatic ,Full Prescribing ,Dow Jones Industrial Average ,Five Prime Therapeutics ,Horizon Therapeutics ,Thousand Oaks ,Accessed May ,